Anticoagulation Bridge Therapy in Patients with Atrial Fibrillation: Recent Updates Providing a Rebalance of Risk and Benefit.

Abstract

In 2011 we reviewed clinical updates and controversies surrounding anticoagulation bridge therapy in patients with atrial fibrillation (AF). Since then, options for oral anticoagulation have expanded with the addition of four direct oral anticoagulant (DOAC) agents available in the United States. Nonetheless, vitamin K antagonist (VKA) therapy continues to be the treatment of choice for patients who are poor candidates for a DOAC and for whom bridge therapy remains a therapeutic dilemma. This literature review identifies evidence and guideline and consensus statements from the last 5 years to provide updated recommendations and insight into bridge therapy for patients using a VKA for AF. Since our last review, at least four major international guidelines have been updated plus a new consensus document addressing bridge therapy was released. Prospective trials and one randomized controlled trial have provided guidance for perioperative bridge therapy. The clinical trial data showed that bridging with heparin is associated with a significant bleeding risk compared with not bridging; furthermore, data suggested that actual perioperative thromboembolic risk may be lower than previously estimated. Notably, patients at high risk for stroke have not been adequately represented. These findings highlight the importance of assessing thrombosis and bleeding risk before making bridging decisions. Thrombosis and bleeding risk tools have emerged to facilitate this assessment and have been incorporated into guideline recommendations. Results from ongoing trials are expected to provide more guidance on safe and effective perioperative management approaches for patients at high risk for stroke.

• Authors: Candice L Garwood, Bianca Korkis, Domenico Grande, Claudia Hanni, Amy Morin, Lynette R Moser
• Journal: Pharmacotherapy (Pharmacotherapy) Vol. 37 Issue 6 Pg. 712-724 (Jun 2017) ISSN: 1875-9114 [Electronic] United States
• PMID: 28475278 (Publication Type: Journal Article, Review)
• Copyright: © 2017 Pharmacotherapy Publications, Inc.

Chemical References

• Anticoagulants
• Heparin

Topics

• Administration, Oral
• Anticoagulants (administration & dosage, adverse effects)
• Atrial Fibrillation (drug therapy, epidemiology)
• Clinical Trials as Topic (methods)
• Heparin (administration & dosage, adverse effects)
• Humans
• Practice Guidelines as Topic (standards)
• Prospective Studies
• Risk Factors
• Stroke (epidemiology, prevention & control)